MAR 10, 2018 3:49 PM PST

Treatment Intended for Osteoarthritis, Decreases Opioid Dependence

WRITTEN BY: Nouran Amin

A research team at the Linda and Jack Gill Center for Biomolecular Science at Indiana University uncovered a unique quality of a compound that was formerly examined for the treatment of osteoarthritis. The compound known as CB2 cannabinoid agonist LY282836 was ineffective in treating osteoarthritis but successful in decreasing opioid dependence when combined with opioid-based pain medications. The CB2 cannabinoid agonist LY282836 was seen to inhibit neuropathic pain while reducing symptoms of opioid addiction. 

Image via NIH Common Fund

Initially, the agonist compound was trialed in individuals with osteoarthritis by the pharmaceutical company Eli Lilly but failed to be effective. So, researchers wanted to understand the purpose of such compound when its role in pain relief was discovered which motivated a study on its use in opioid-dependence.

Now, the potentiality of the compound to treat an opioid-addiction may be considered for another clinical trial. Lead investigator and professor of Neuroscience at Indiana University, Dr. Andrea G. Hohmann, explains that "The potential to quickly begin using this compound in combination with opioid-based medication to treat pain and reduce addiction makes this discovery very significant”. There is a particular advantage to reexamine the effects of the compound in a different context. "We already know this drug is safe for use in people, so moving into human trials will not require as many regulatory hurdles," says Dr. Hohmann.

There is an urgency to develop pain medications that are non-addictive. The opioid crisis has killed over 64,000 Americans in 2016 and the number is growing due to opioid overdose.

 

To see if CB2 cannabinoid agonist LY282836 may be the answer to end the opioid crisis. Researchers tested the experimental drug in combination with an opioid morphine and administered the substance in mouse models that exhibit neuropathic pain. The results showed a quick response to morphine’s effectiveness. The mice developed morphine tolerance despite the morphine’s pain reduction purpose. This correlated to the symptoms displayed in humans who need high amounts of opioids as time progresses in order to relieve pain. On the other hand, when a low dose of the agonistic compound is administered in combination with morphine, then the ability to develop tolerance to has failed even after the use of the agonist has discontinued. Furthermore, the experimental drug was able to sustain pain relief at higher doses.

Following another experiment, the morphine was administered to mice free of the experimental drug or in a combination of the drug; and in either case, they were treated with naloxone, known to reverse an opioid overdose. The experimental drug also lessened the severity of symptoms associated with an opioid withdrawal.

The results concluded that to maintain a satisfactory treatment and reduce symptoms of an opioid dependence, then opioids must be taken in combination with the experimental drug.

Results of this study were published in the Journal of Molecular Pharmacology.

Sources: Indiana University, Journal of Molecular Pharmacology, DrugAbuse.gov

 

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 04, 2019
Neuroscience
DEC 04, 2019
Single Dose Ketamine Could Rewire Alcohol, Drug Dependance
Presentation by Tobias Stephenson about previous research exploring ketamine as an addiction treatment.    Researchers at University College Lond...
DEC 09, 2019
Drug Discovery & Development
DEC 09, 2019
Could the diabetic drug 'metformin' extend a healthy lifespan?
The most commonly prescribed diabetic medication for the Type 2 condition is ‘Metformin’—a drug with a mysterious mechanism of action but...
JAN 14, 2020
Drug Discovery & Development
JAN 14, 2020
Promising Treatment for Dementia: Antibiotics
A class of antibiotics, known as the ‘aminoglycosides’ may serve as a promising treatment for frontotemporal dementia—according to resear...
JAN 15, 2020
Cancer
JAN 15, 2020
Hope for patients with AML
Research published recently in the medical journal EMBO Molecular Medicine brings hope for leukemia patients with a report that a common and cheap drug may...
JAN 15, 2020
Drug Discovery & Development
JAN 15, 2020
A New Drug Target for Substance Abuse
Research carried out by the University of Minnesota Medical School indicates a new drug target for treating a drug addiction. Researchers note that the dru...
FEB 17, 2020
Cancer
FEB 17, 2020
Listening in on cancer cells
Research published today in Nature Methods reports a new technique of “listening” to cancer cells. While it may sound odd (no pun intended...
Loading Comments...